Aurobindo Pharma's Profit Surge Highlights Sharp Margin Expansion
The company delivered a 31.9% YoY jump in profit, driven by a significant improvement in net profit margin to 26.3%.
Aurobindo Pharma's Q1 FY27 results show a powerful profit rebound. While revenue was stable, net profit surged nearly 32% year-on-year as the company's net profit margin expanded sharply.
Aurobindo Pharma has kicked off FY27 with a quarter of impressive profitability. While overall revenue saw a slight year-on-year dip, the company's net profit surged by nearly a third, powered by a significant expansion in its net profit margin.
The story is one of improving efficiency. Revenue for Q1 FY27 came in at ₹2,799.5 crore, a marginal 0.5% increase over the previous quarter but down 1.7% from the same period last year. Profit, however, tells a different tale. It rose to ₹737.2 crore, marking a robust 31.9% year-on-year and a solid 6.5% sequential growth. This divergence pushed the net profit margin to 26.3%, up from 19.6% a year ago and continuing an upward trend over recent quarters.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 2,799.5YoY -1.7% | 2,786.6 | 2,848.2 |
| Profit (₹ Cr) | 737.2YoY +32% | 692.2 | 559.1 |
| Net Profit Margin (%) | 26.3YoY +34% | 24.8 | 19.6 |
The table illustrates a clear multi-quarter trend of rising profitability. Over the past five quarters, profit has grown consistently even as revenue has remained in a tight range, showcasing the company's focus on operational leverage and cost management. This performance has translated into strong trailing twelve-month (TTM) metrics, with a profit of ₹2,592.9 crore and a TTM net profit margin of 23.3%.
Key Points
- Strong Balance Sheet: The company maintains a conservative debt profile with a low debt-to-equity ratio of 0.2 and a healthy interest coverage ratio of over 14 times.
- Market Performance: The stock has significantly outperformed over the past year, delivering a 48.2% return, which reflects growing investor confidence in its earnings trajectory.
- Valuation Context: Despite the recent run-up, Aurobindo trades at a P/E of 21.6, which represents a substantial discount of roughly 42% to the broader pharmaceutical industry average.
The key question for the coming quarters is whether Aurobindo can sustain these elevated profit margins while reigniting top-line growth.
Live Chart
· AUROPHARMA
(BSE)
ISIN: INE406A01037
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.